Previous 10 | Next 10 |
Gainers: Camber Energy (NYSE:CEI) +97%. Merus (NASDAQ:MRUS) +32%. New Fortress Energy (NASDAQ:NFE) +25%. Paltalk (NASDAQ:PALT) +25%. Grom Social Enterprises (NASDAQ:GROM) +20%. DatChat (NASDAQ:DATS) +20%. Jupiter Wellness (NASDAQ:JUPW) +18%. NextPlay Technologies (NASDAQ:NXTP) +19%. Independe...
NEWTON, Mass. and GENEVA, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER) (“Acer”) and its collaboration partner, RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF) (“Relief”), today announced that the U.S. Patent and Trademark Office...
FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Acer Therapeutics Inc. and Relief Therapeutics Announce FDA Acceptance for Filing of New Drug Application for ACER-001” Acer Therapeutics Inc. (NASDAQ: ACER) c...
Gainers: Voyager (NASDAQ:VYGR) +44%. Grom Social Enterprises (NASDAQ:GROM) +26%. Bit Digital (NASDAQ:BTBT) +16%. Resonant (NASDAQ:RESN) +16%. Affirm Holdings (NASDAQ:AFRM) +14%. Acer (NASDAQ:ACER) +12%. Acuity Brands (NYSE:AYI) +12%. SGOCO Group (NASDAQ:SGOC) +14%. Xenon Pharmaceuticals (NASD...
Gainers: Voyager Therapeutics (NASDAQ:VYGR) +57%, Acer Therapeutics (NASDAQ:ACER) +9%, Molecular Partners (NASDAQ:MOLN) +10%, Rafael (NYSE:RFL) +6%, Arcturus Therapeutics (NASDAQ:ARCT) +7%. Losers: Ginkgo Bioworks (NYSE:DNA) -21%, OpGen (...
NEWTON, Mass. and GENEVA, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER) (“Acer”) and its collaboration partner, RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF) (“Relief”), today announced that the U.S. Food and Drug Administratio...
Voyager Therapeutics (NASDAQ:VYGR) +44% Pfizer in pact with Voyager Therapeutics to develop gene therapies Acer Therapeutics (NASDAQ:ACER) +14%. Kaixin Auto (NASDAQ:KXIN) +8% as POCCO EV orders surpassed 3000 units in September, +130% M/M Palantir Technologies (NYSE:PLTR)&...
Acer Therapeutics is a pharmaceutical company that acquires, develops and seeks to commercialize therapies for serious, rare, and life-threatening diseases. Acer submitted an NDA for its lead drug candidate ACER-001 for treatment of UCDs in early August. Acer expects notification ...
NEWTON, Mass., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced th...
NEWTON, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today reported fin...
News, Short Squeeze, Breakout and More Instantly...
Acer Therapeutics Inc. Company Name:
ACER Stock Symbol:
NASDAQ Market:
Acer Therapeutics Inc. Website:
AERWINS Technologies Inc. (AWIN) is expected to report for Q1 2024 Minera IRL Ltd ADR (MRLLY) is expected to report for quarter end 2023-09-30 SmileDirectClub, Inc. - Ordinary Shares - Class A (SDCCQ) is expected to report $-0.1 for Q3 2023 NextPlay Technologies Inc. (NXTP) is expecte...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Acer Therapeutics Inc. (ACER) is expected to report $-0.13 for Q3 2023